

NOVO NORDISK A S  
Form 6-K  
April 30, 2013

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

**April 30, 2013**

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_



**Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2013**

**Bagsværd, Denmark, 30 April 2013** – In accordance with Section 6 of the Danish Statutory Order on Issuers’ Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred.

Referring to Company Announcement no 28/2013 dated 22 April 2013, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 30 April 2013.

	<b>Number of shares</b>	<b>Nominal value</b>	<b>Number of votes</b>
	<b>(nominal value DKK 1)</b>	<b>(DKK)</b>	
<b>A shares</b>	<b>107,487,200</b>	<b>107,487,200</b>	<b>107,487,200,000</b>
<b>B shares</b>	<b>442,512,800</b>	<b>442,512,800</b>	<b>44,251,280,000</b>

*Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 35,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com).*

**Novo Nordisk A/S**  
Investor Relations  
Novo Allé  
2880 Bagsværd  
Denmark

Telephone: +45 4444 8888  
CVR no: 24 25 67 90  
Internet:  
[www.novonordisk.com](http://www.novonordisk.com)

Company announcement No 31 / 2013



**Further information**

*Media:*

Anne Margrethe Hauge  
Ken Inchausti (US)

+45 4442 3450  
+1 609 514 8316

[amhg@novonordisk.com](mailto:amhg@novonordisk.com)  
[kiau@novonordisk.com](mailto:kiau@novonordisk.com)

*Investors:*

Kasper Roseeuw Poulsen  
Frank Daniel Mersebach  
Lars Borup Jacobsen  
Jannick Lindegaard (US)

+45 4442 4303  
+45 4442 0604  
+45 3075 3479  
+1 609 786 4575

[krop@novonordisk.com](mailto:krop@novonordisk.com)  
[fdni@novonordisk.com](mailto:fdni@novonordisk.com)  
[lbpj@novonordisk.com](mailto:lbpj@novonordisk.com)  
[jlis@novonordisk.com](mailto:jlis@novonordisk.com)

**Novo Nordisk A/S**    Novo Allé  
Investor Relations    2880 Bagsværd  
                                  Denmark

Telephone:                    CVR no:  
+45 4444 8888                24 25 67 90  
Internet:  
[www.novonordisk.com](http://www.novonordisk.com)

Company announcement No 31 / 2013

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: April 30, 2013

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer